相关实验视频

Updated: Sep 19, 2025

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

在非常低梯度的大动脉狭窄症中进行过导管大动脉植入

Connor Raikar¹, Abigail S Baldridge², Zhiying Meng²

¹Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Structural heart : the journal of the Heart Team

|June 18, 2025

概括

过导管大动脉植入 (TAVI) 有利于患有非常低梯度大动脉狭窄症 (VLGAS) 的患者,改善症状和生活质量. 然而,症状改善在一年后会减弱,VLGAS患者的再入院率更高.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
心脏外科手术心脏外科手术

背景情况:

严重的大动脉狭窄症是一个重大的临床挑战.
通过导管的大动脉植入 (TAVI) 是为低梯度大动脉狭窄症 (LGAS) 建立的.
在极低梯度大动脉狭窄症 (VLGAS) 中TAVI的结果仍然不太清楚.

研究的目的:

评估TAVI在VLGAS患者中的疗效和结果.
为了比较不同梯度和流量亚组的TAVI结果在严重的大动脉狭窄.
评估TAVI后的症状和生活质量改善,再住院和死亡率.

主要方法:

对1173名因严重大动脉狭窄而接受TAVI的患者进行了回顾性队列研究.
患者分为VLGAS (MPG ≤25 mmHg),LGAS (25-40 mmHg) 和高梯度 (≥40 mmHg) 组.
基于经典的低流量,矛盾的低流量和正常流量状态的子组分析.

主要成果:

在大多数VLGAS患者中,TAVI导致了症状和生活质量的改善.
在VLGAS患者1年后,症状改善的显著减少 (p < 0.01).
VLGAS患者经历了最高的一年再住院率 (p < 0.01);其他结果在各组中都相似.

结论:

塔维有效改善LGAS患者的症状和生活质量,包括VLGAS患者.
在VLGAS的1年后,症状的改善会减少,特别是在正常流量亚组中.
死亡率和再住院的差异主要在经典的低流量VLGAS亚组中观察到.

关键词:

大动脉狭窄症大动脉狭窄症低流量低梯度的大动脉狭窄症穿过导管的大动脉植入装置.

更多相关视频

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

相关概念视频

Mitral Stenosis III: Medical Management

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

Mitral Stenosis I: Introduction

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...